ArticleScientific reports2025
Synergistic design of CuO/CoFe₂O₄/MWCNTs ternary nanocomposite for enhanced photocatalytic degradation of tetracycline under visible light.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Green Synthesis and Characterization of ZnO/CoFeMolecules (Basel, Switzerland) · 2026Article
- Z-Scheme CoFeRSC advances · 2026Article
- Facile Preparation of a Plasmon-Enhanced Ag-CuO/TiOMaterials (Basel, Switzerland) · 2026Article
- Enhanced photocatalytic degradation of tetracycline using cobalt-substituted ZnFeScientific reports · 2025Article
- Sustainable synthesis of alginate-cobalt ferrite nanocomposites for horseradish peroxidase immobilization: enhanced stability, reusability, and catalytic efficiency.Bioprocess and biosystems engineering · 2025Article
- Sustainable synthesis of iron-doped manganese oxide nanoparticles for effective photo-accelerated detoxification of tetracycline.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study involves a novel CuO/CoFe₂O₄/MWCNTs (CCT) nanocomposite, developed by integrating cobalt ferrite (CoFe₂O₄) and copper oxide (CuO) nanoparticles onto multi-walled carbon nanotubes (MWCNTs), for the degradation of tetracycline (TC) under visible light. The photocatalyst was extensively characterized using XRD, HR-SEM, EDX, HR-TEM, UV-Vis, BET, and PL analysis. The synthesized CoFe₂O₄ and CuO nanoparticles exhibited crystallite sizes of 46.8 nm and 37.5 nm, respectively, while the CCT nanocomposite had a crystallite size of 53 nm. Microscopy confirmed a particle size of 49.2 nm for the nanocomposite, with MWCNTs measuring 15.65 nm in diameter. The band gap energy of the CCT nanocomposite was 1.6 eV, which contributed to its enhanced photocatalytic activity, as evidenced by the lower emission intensity in PL analysis. BET analysis revealed a pore volume of 0.37 cc/g and a surface area of 82.3 m²/g. Photocatalytic performance was tested across various conditions, with adjustments to nanocomposite dosages (0.1-0.5 g/L), TC concentrations (5-25 mg/L), and pH levels (2-10). Under optimized conditions (0.3 g/L CCT, 5 mg/L TC, pH 10, 120 min of visible light exposure), the CCT achieved 98.1% degradation of TC. The optimized parameters were subsequently used to assess TC degradation with individual photocatalysts: CoFe₂O₄, CuO, CT, and CCT. The enhanced photocatalytic efficiency observed can be largely attributed to the improved charge transfer dynamics and effective electron-hole separation facilitated by MWCNT doping. The reaction followed a pseudo-first-order kinetic model, with hydroxyl radicals (OH
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.